AKR1C3, overexpressed in various cancer tissues, has been associated with disease progression and poor prognosis, playing a pivotal role in resistance to multiple cancer treatment modalities, including radiation, chemotherapy drugs, and steroid drugs. Here, AKR1C3 is linked to cancer.